This is in accordance with previous studies showing that wtp53 down-modulates MGMT [22, 23], and a recent study showing that systemic delivery of wtp53 plasmid DNA using an immunoliposome nanocomplex to intracranial GBM tumors decreased MGMT and increased response of TMZ-resistant GBM tumors to TMZ in a mouse model [88]. This evidence concerns the gene MGMT and glioblastoma.